When was Hatchtech founded?

Hatchtech was founded in 2001 and raised its 1st funding round within a year of its incorporation.

Where is Hatchtech located?

Hatchtech is headquartered in Camberwell, Australia.

How many employees does Hatchtech have?

As of Aug 31, 2026, the latest employee count at Hatchtech is 4.

Is Hatchtech a funded company?

Hatchtech is a funded company, having raised a total of $31.4M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2001.

When was the latest funding round of Hatchtech?

Hatchtech's latest funding was a $***** Series B round on Oct 31, 2013, with participation from 3 investors.

Where does Hatchtech rank among its competitors?

Hatchtech ranks 2nd amongst 15 active competitors, of which 4 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Astra, which secured $9.77M in Jul, 2025.

Who are the top competitors of Hatchtech?

Hatchtech's top competitors include La Jolla Pharmaceutical, Astra and Acetylon. Among them, Astra secured the most recent funding round in July, 2025.

Hatchtech - 2026 Company Profile, Team, Funding & Competitors

Company Details

Hatchtech, a specialty pharmaceutical company developing Xeglyze Lotion (previously DeOvoLotion ), a proprietary next generation head lice treatment. Xeglyze is a topical lotion containing an inhibitor of metalloproteinases known to impede a number of physiological processes involved in all stages of the louse lifecycle from egg to adult. Xeglyze Lotion recently completed two phase III clinical studies conducted under a Special Protocol Agreement with the U.S. Food and Drug Administration (FDA).

Website: hatchtech.com.au
Social

Key Metrics

Founded Year

2001

Location

Camberwell, Australia

Stage

Series B

Total Funding

$31.4M in 6 rounds

Latest Funding Round

Series B, Oct 31, 2013, $*****

Investors

GBS & 4 more

Ranked

2^nd among 15 active competitors

Employee Count

4 as on Aug 31, 2026

Similar Companies

La Jolla Pharmaceutical & 16 more

View Hatchtech's full profile

Hatchtech has raised a total funding of $31.4M over 6 rounds. Its first funding round was on 2001. Its latest funding round was a Series B round on Oct 31, 2013 for $*****. 3 investors participated in its latest round. Hatchtech has 5 institutional investors.

Here is the list of recent funding rounds of Hatchtech:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 31, 2013	7203528	Series B	7926537	7439810	6794876	4299593
Apr 26, 2012	8833728	Series B	7918458	7220613	3285627	GBS & 2 more
Oct 26, 2010	7459692	Series A	2413029	1118268	4301284	One Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Hatchtech's funding rounds and investors

The founders of Hatchtech is Vern Bowles.

Here are the details of Hatchtech's key team members:

Vern Bowles: Founder & CSO of Hatchtech.
Contact Info: 1 email address
Hugh Alsop: CEO of Hatchtech.

View details of Hatchtech's Founder profiles and Board Members

Hatchtech's employee count trend

Hatchtech has 4 employees as of Aug 26. Here is Hatchtech's employee count trend over the years:

Uncover Hatchtech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Hatchtech include La Jolla Pharmaceutical, Astra and Acetylon. Here is the list of Top 10 competitors of Hatchtech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	La Jolla Pharmaceutical 1989, San Diego (United States), Acquired	Innovating critical care and infectious disease therapies for global health	-	Colt Ventures, RTW Investments & 4 others	54/100
2nd	Hatchtech 2001, Camberwell (Australia), Series B	Developer of proprietary head lice drugs	$31.4M	GBS, University of Melbourne & 3 others	52/100
3rd	Astra 2019, Villigen (Switzerland), Seed	Developer of small molecule anti-parasitic drugs using structural data	$9.77M	Digitalis Ventures, MIG Fonds & 3 others	49/100
4th	Acetylon 2008, Boston (United States), Acqui-Hired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$138M	Celgene, The Kraft Group & 2 others	41/100
5th	Topaz Pharmaceuticals 2005, Horsham (United States), Acquired	Pediatric medicines for treatment of head lice	$20.8M	Ben Franklin Technology Partners, Aisling Capital ... & 2 others	35/100
6th	Abgenics Life Sciences 2010, Pune (India), Funding Raised	Developer of drugs for intestinal worm infections using probiotic strains of the bacterium Lactobacillus	-	Gates, C-CAMP & 3 others	34/100
7th	Zero Point Five Therapeutics 2018, Baltimore (United States), Series A	Developer of therapeutics for infectious diseases	$11.5M	-	33/100
8th	KAINOMYX 2019, San Francisco (United States), Seed	Developer of therapeutic solutions for treating malaria and other parasitic diseases	$13.5M	IISD, C-CAMP & 1 others	32/100
9th	TYDOCK PHARMA 2006, Modena (Italy), Funding Raised	Developer of chemotherapeutic drugs for parasitic diseases	-	EIC Fund, Europa	29/100
10th	NemaGen 2019, Cranbury (United States), Funding Raised	Developer of therapies for allergic inflammation and mast cell-related diseases	-	Foundation Venture Capital Group, HHS	28/100